Anti-LAG3 antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-10358495-B2
Application number	US-201615289032-A
Country	US
Kind code	B2
Filing date	Oct 7, 2016
Priority date	Oct 9, 2015
Publication date	Jul 23, 2019
Grant date	Jul 23, 2019

Abstract

The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.

First claim

What is claimed is:

1. An isolated antibody or antigen-binding fragment thereof that binds specifically to human lymphocyte activation gene 3 (LAG3) protein, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) amino acid sequence of SEQ ID NO: 418 and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) amino acid sequence of SEQ ID NO: 426.

2. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof interacts with one or more amino acids contained within the extracellular domain of LAG3 (amino acids 28-71 of SEQ ID NO: 588), as determined by hydrogen/deuterium exchange.

3. The isolated antibody or antigen-binding fragment of claim 2 wherein the antibody or antigen-binding fragment thereof interacts with one or more amino acids contained within SEQ ID NO: 589, as determined by hydrogen/deuterium exchange.

4. The isolated antibody or antigen-binding fragment of claim 2 , wherein the antibody or antigen-binding fragment thereof interacts with an amino acid sequence selected from the group consisting of (a) amino acids 28 to 69 of SEQ ID NO: 588; (b) amino acids 28 to 71 of SEQ ID NO: 588; (c) amino acids 31 to 52 of SEQ ID NO: 588; and (d) amino acids 32 to 69 of SEQ ID NO: 588.

5. The isolated antibody or antigen-binding fragment thereof of claim 3 wherein the antibody or antigen-binding fragment thereof interacts with at least ten amino acids contained within SEQ ID NO: 589.

6. The isolated antibody or antigen-binding fragment thereof of claim 3 , wherein the antibody or antigen-binding fragment thereof interacts with at least twenty amino acids contained within SEQ ID NO: 589.

7. The isolated antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof interacts with the amino acid sequence of SEQ ID NO: 589.

8. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof has one or more properties selected from the group consisting of:
(a) binds monomeric human LAG3 with a binding dissociation equilibrium constant (K D ) of less than about 1.5 nM as measured in a surface plasmon resonance assay at 25° C.;
(b) binds monomeric human LAG3 with a K D less than about 2 nM as measured in a surface plasmon resonance assay at 37° C.;
(c) binds dimeric human LAG3 with a K D less than about 20 pM as measured in a surface plasmon resonance assay at 25° C.;
(d) binds dimeric human LAGS with a K D less than about 90 pM as measured in a surface plasmon resonance assay at 37° C.;
(e) binds to a hLAG3-expressing cell with an EC 50 less than about 2 nM as measured in a flow cytometry assay;
(f) binds to a mfLAG3-expressing cell with a EC 50 less than about 2.3 nM as measured in a flow cytometry assay;
(g) blocks binding of hLAG3 to human MHC class II with IC 50 less than about 20 nM as determined by a cell adherence assay;
(h) blocks binding of hLAG3 to mouse MHC class II with IC 50 less than about 15 nM as determined by a cell adherence assay;
(i) blocks binding of hLAG3 to MHC class II by more than 90% as determined by a cell adherence assay;
(j) rescues LAG3-mediated inhibition of T cell activity with EC 50 less than about 2.5 nM as determined in a luciferase reporter assay; and
(k) binds to activated CD4+ and CD8+ T cells with EC 50 less than about 1.2 nM, as determined in a fluorescence assay.

9. The isolated antibody or antigen-binding fragment thereof of claim 1 comprising a HCVR having the amino acid sequence of SEQ ID NO: 418.

10. The isolated antibody or antigen-binding fragment thereof of claim 1 comprising a LCVR having the amino acid sequence of SEQ ID NO: 426.

11. The isolated antibody or antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 comprising amino acid sequences of SEQ ID NOs: 420-422-424-428-430-432.

12. The isolated antibody or antigen-binding fragment of claim 11 , wherein the antibody or antigen-binding fragment thereof comprises a HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 418/426.

13. The isolated antibody of claim 12 comprising a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence of SEQ ID NO: 577.

14. The isolated antibody of claim 12 comprising a heavy chain and a light chain, wherein the light chain comprises an amino acid sequence of SEQ ID NO: 578.

15. The isolated antibody or antigen-binding fragment of claim 12 comprising a heavy chain/light chain amino acid sequence pair of SEQ ID NOs: 577/578.

16. A pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier or diluent.

17. An isolated antibody or antigen-binding fragment thereof that binds specifically to human LAG3 protein, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain/light chain amino acid sequence pair of SEQ ID NOs: 577/578.

18. A pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof of claim 17 and a pharmaceutically acceptable carrier or diluent.

Assignees

• Regeneron Pharma

Inventors

• Ullman Erica
• Hermann Aynur
• Ioffe Ella
• Burova Elena
• Thurston Gavin

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title